PacBio Q2 FY26 net loss widens to $44.7 million; revenue slips 2% to $39 million

Reuters2026/08/05 20:52

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pacific Biosciences posted Q2 2026 revenue of USD 39 million, down 2% year over year; consumables rose 6% to USD 20.1 million.
GAAP net loss widened to USD 44.7 million while GAAP net loss per share held at USD 0.14.
GAAP gross margin fell 5 percentage points to 32% due to higher compute and memory costs, Vega manufacturing transition costs, lower Revio average selling prices.
Revio system placements climbed to 20, Vega placements slipped to 26; annualized Revio pull-through per system eased to about USD 202,000.
Forecast 2026 revenue of USD 155 million to USD 165 million; began global SPRQ-Nx rollout, listing whole-genome sequencing at USD 345 per genome.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacific Biosciences of California Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608051605PRIMZONEFULLFEED9804409) on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

PacBio Q2 FY26 net loss widens to $44.7 million; revenue slips 2% to $39 million

You may also like

Crypto prices